Healthcare / BiotechnologyNasdaqCM
$28.51
+2.34 (+8.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-6.9M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$395M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-5480.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-19.4M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-19.4M | $-19.4M | $-15.8M | $-8.9M | $-7.8M | $-4.6M | $-1.9M | $-3.4M |
| EBITDA | — | — | $-16.0M | $-9.3M | $-8.0M | $-4.6M | — | — |
| EPS | -1.43 | -1.43 | -1.21 | -0.69 | -0.61 | -0.35 | — | — |
| Balance Sheet | ||||||||
| Current Ratio | — | — | 2.35 | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | — | — | $-7.3M | $-6.5M | $-6.2M | $-4.3M | — | — |
| Returns | ||||||||
| ROE | -5480.5% | -5480.5% | -623.1% | -132.7% | -59.2% | -17.0% | -6.7% | 253.6% |
| Valuation | ||||||||
| P/B | — | — | 146.42 | 18.60 | 14.44 | 10.43 | — | — |
| Growth & Yield | ||||||||
| EPS Growth | -6.7% | -6.7% | -75.4% | -13.1% | -74.3% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+189.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.21 → -1.43
Residual
+189.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.